The filing is a routine insider sale notice for tax-related share settlement. The amount is small relative to market cap and the officer's likely total holdings. No material impact on the stock is expected.
ZYME drugs
ZYME drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $26.24entry
- T+1 · 15h ago +0.80%α +2.71% · $26.45
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Paul Andrew Moore, an officer of Zymeworks, filed a Form 144 notice of intent to sell 39,741 shares of common stock worth approximately $1.05 million. The shares were acquired through vesting of restricted stock units and exercise of options. The sale is small relative to the company's $2.0 billion market cap (about 0.05%) and appears to be a routine exercise-and-sell-to-cover transaction for tax obligations.
Key Facts
- Reporting person: Paul Andrew Moore, an officer of Zymeworks Inc.
- Shares to be sold: 39,741 shares of common stock
- Approximate dollar value: $1,051,944.27
- Shares acquired via vesting of RSUs (Jan 2024, Jan 2025) and exercise of options (Nov 2026)
- Sale intended to be executed on or about November 13, 2026
- Broker: Morgan Stanley Wealth Management Canada
Financial Impact
Sale of $1.05 million represents approximately 0.05% of the company's $2.0 billion market cap
Risk Factors
- Insider sales can signal lack of confidence if large relative to holdings, but this sale is small and appears tax-motivated
- Form 144 is an intent to sell; the actual sale may not occur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001938192-26-000005 |
| Document: 0001938192-26-000005-index.html | 0001938192-26-000005 |
| Document: 0001938192-26-000005.txt | 0001938192-26-000005 |
Track record
25 reports on ZYME
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Viewing Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers